Sitemap Contact Privacy Statement Imprint

Breast Cancer Epigenetics: Predictive Factors of Drug Treatment Outcome

The high recurrence rates observed in breast cancer drug treatment are attributed to treatment failure and resistance. Up to the present, it remains unclear, why some patients benefit and others don’t. A prominent approach to overcome these limitations is the personalization of current endocrine/chemotherapeutic drug treatment strategies. This requires the availability of powerful biomarkers. Recently, epigenetic principles have attracted major attention and it has become clear, that DNA methylation, histone modification and microRNA deregulation may qualify as treatment predictors. To follow this up within the context of breast cancer, we are particularly interested whether genetic (e.g. miRNA genes) and epigenetic variations can be used to predict the outcome of endocrine and chemotherapy. Our research focuses on the role of promoter sequence methylation of various genes in potentially relevant pathways as well as deregulated miRNA signatures (profiling) in distinct patient cohorts. It is expected that qualified treatment predictors will help to control breast cancer recurrence and mortality rates.




Major Projects
  • breast tumor epigenetics (miRNA, promoter methylation)
  • anti-cancer drug sensitivity/resistance (therapy prediction)
  • epigenome (miRNAome/methylome) – transcriptome relationships (e.g. miRNA/mRNA target scans)
  • microRNA gene regulation (genetics and epigenetics)
Dr. Reiner Hoppe

phone: ++49-711-8101 3712

Selected References
Original Articles
  • Hoppe R, Brauch H, Kroetz DL, Esteller M. Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine. Genome Biol. 2011 Jan 17;12(1):301
  • Kaipparettu BA, Malik S, Konduri SD, Liu W, Rokavec M, van der Kuip H, Hoppe R, Hammerich-Hille S, Fritz P, Schroth W, Abele I, Das GM, Oesterreich S, Brauch H. Estrogen-mediated downregulation of CD24 in breast cancer cells. Int J Cancer 2008 Jul 1;123(1):66-72.
  • Hoppe R, Breer H, Strotmann J. Promoter motifs of olfactory receptor genes expressed in distinct topographic patterns. Genomics 2006 Jun;87(6):711-23. Epub 2006 Apr 4.
  • Hoppe R, Lambert TD, Samollow PB, Breer H, Strotmann J. Evolution of the "OR37" subfamily of olfactory receptors: a cross-species comparison. J Mol Evol 2006 Apr;62(4):460-72. Epub 2006 Mar 17.
  • Hoppe R, Frank H, Breer H, Strotmann J. The clustered olfactory receptor gene family 262: genomic organization, promotor elements, and interacting transcription factors. Genome Res 2003 Dec;13(12):2674-85.
  • Hoppe R, Breer H, Strotmann J. Organization and evolutionary relatedness of OR37 olfactory receptor genes in mouse and human. Genomics 2003 Sep;82(3):355-64.
  • Hoppe R, Weimer M, Beck A, Breer H, Strotmann J. Sequence analyses of the olfactory receptor gene cluster mOR37 on mouse chromosome 4. Genomics 2000 Jun 15;66(3):284-95.
  • Strotmann J, Hoppe R, Conzelmann S, Feinstein P, Mombaerts P, Breer H. Small subfamily of olfactory receptor genes: structural features, expression pattern and genomic organization. Gene 1999 Aug 20;236(2):281-91.

Selected Reviews
  • Breer H, Hoppe R, Kaluza J, Levai O, Strotmann J. Olfactory subsystems in mammals: specific roles in recognizing chemical signals? Chem Senses 2005 Jan;30 Suppl 1:i144-5. No abstract available.
Major Networks and Collaborations
  • 7 FP EU Initial Training Network (Marie Curie PhD training programme “FightingDrugFailure”)

Curriculum Vitae Reiner Hoppe, PhD

Affiliation
Principal Investigator at the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP), Stuttgart, Germany

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen
Auerbachstr. 112
D - 70376 Stuttgart Germany
phone: ++49-(0)711-8101-3712
fax: ++49-(0)711-85 92 95
email: reiner.hoppe@ikp-stuttgart.de
Education and Professional Career
1991 -1996 Study of biology, University of Hohenheim, Stuttgart, Germany
1997 Diploma in biology, University of Hohenheim, Stuttgart, Germany
1998 - 2002 PhD thesis: “Characterization of cluster organization and molecular studies for the identification of putative control elements of olfactory receptor genes”; Institute of Physiology, University of Hohenheim, Stuttgart (Prof. Dr. H. Breer)
2002 Dr. rer. nat. (PhD) in biology, University of Hohenheim, on gene expression control of olfactory receptor genes
2003 - 2006 Postdoctoral Research Fellow at Institute of Physiology, University of Hohenheim, Stuttgart, on gene expression control of olfactory receptor genes and hormone receptors in chemosensory systems
1/2007 - present Principal Investigator at Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany